Form 4: ARS Pharmaceuticals CEO Receives Stock Grant
Insider Transaction (Form 4)
Donn Casale, President and CEO and a Director of ARS Pharmaceuticals, Inc., received 1,036,923 shares of common stock on October 1, 2026.
Summary
- Grant/award: acquired 1,036,923 Stock Option (right to buy) on October 1, 2026; holds 1,036,923 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Donn Casale — Director, Officer (President and CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-01 | Grant/award | Stock Option (right to buy) | 1,036,923 | — | — | 1,036,923 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-01 | Grant/award (1,036,923 shares) |
Keywords
insider transaction, Form 4, SPRY, ARS Pharmaceuticals, Inc., neutral, Donn Casale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.